StockData
Keros Therapeutics, Inc. logo

Keros Therapeutics, Inc. (KROS) stock

KROSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$11.31+1.28 (+12.76%)

Close on Nov 17, 2026Market cap $224.25MP/E –Yield –

Keros Therapeutics operating margin

Operating margin is operating income as a percentage of revenue.

Keros Therapeutics's operating margin for the twelve months ending Jun 30, 2026 was -698.0%. For fiscal 2025 it was 27.7%, against -112543.7% the year before.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202527.7%+112571.4
FY2023Dec 31, 2023-112543.7%−112263.2
FY2021Dec 31, 2021-280.5%−174.8
FY2019Dec 31, 2019-105.6%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q1 FY2026Mar 31, 2026-80865.6%−80937.6
Q4 FY2025Dec 31, 2025-7702.6%+24783.4
Q3 FY2025Sep 30, 2025-108.9%+540891.1
Q2 FY2025Jun 30, 2025-219.2%−194.8
Q1 FY2025Mar 31, 202572.0%+15613.0
Q4 FY2023Dec 31, 2023-32486.0%−32376.9
Q3 FY2023Sep 30, 2023-541000.0%−540907.0
Q4 FY2021Dec 31, 2021-24.3%+81.7
Q2 FY2021Jun 30, 2021-15541.0%−15426.7
Q4 FY2019Dec 31, 2019-109.1%–
Q3 FY2019Sep 30, 2019-93.0%–
Q2 FY2019Jun 30, 2019-106.0%–
Q1 FY2019Mar 31, 2019-114.3%–

More Keros Therapeutics figures

See a number that looks wrong?